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A B S T R A C T
An amyloid precursor protein (APP) A673T mutation was found to be protective against Alzheimer's disease
(AD) and cognitive decline in the Icelandic population and to associate with decreased levels of plasma β-
amyloid in a Finnish population-based cohort. Human fibroblasts from a Finnish male individual carrying the
protective mutation were used to generate integration-free induced pluripotent stem cell (iPSCs) line by Sendai
virus technology. The iPSC line retained the mutation and expressed pluripotency markers, had a normal kar-
yotype and differentiated into all three germ layers.
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Institution A.I.Virtanen Institute for Molecular
Sciences
University of Eastern Finland
Contact information of
distributor
Jari Kostinaho, jari.koistinaho@uef.fi; jari.
koistinaho@helsinki.fi
Type of cell line iPSC
Origin Human
Additional origin info Age: 65
Sex: male
Ethnicity if known: Finnish




Sendai virus delivery of OCT-3/4, KLF-4,
SOX-2 and c-MYC genes
Genetic Modification NO modification
Type of Modification NO modification
Associated disease Protective against Alzheimer's disease






Name of transgene or
resistance










Ethical approval Northern Savo Hospital district (license no.
123/2016)
Resource utility
Alzheimer's disease (AD) is the leading cause of dementia world-
wide. While several mutations in APP gene are responsible for familial
early-onset AD, APP A673T mutation is associated with reduced risk for
https://doi.org/10.1016/j.scr.2018.05.014
Received 10 May 2018; Accepted 18 May 2018
⁎ Corresponding author at: A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
E-mail address: jari.koistinaho@uef.fi (J. Koistinaho).
Stem Cell Research 30 (2018) 96–99
Available online 19 May 2018
1873-5061/ © 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
AD. The generated line could be used for in vitro modeling to explore
the mechanism behind its protective role.
Resource details
The APP is best known for being a precursor molecule for β-amyloid
(Aß). The fibrillar form Aß is the primary component of amyloid pla-
ques found in the brain of AD patients. Here, we report the generation
of an iPSC line from a 65-year old male expressing a rare c.2017G>A
variant in the APP gene. This substitution is next to the aspartyl pro-
tease β-site in APP and results in an approximately 40% reduction in
the formation of Aß peptides in vitro (Jonsson et al. 2012). Moreover,
carriers of the APP A673T variant have 28% lower levels of Aß40 and
Aß 42 in plasma (Martiskainen et al. 2017).
Fibroblasts were reprogrammed using CytoTune™-iPS 2.0 Sendai
Reprogramming Kit. The colonies were manually picked and expanded
clonally. Four clones were selected based on morphology for further
characterization using methods described previously (Holmqvist et al.
2016). Here, we present the detailed characterization for clone
MADGIC 4A. The expression of pluripotency-promoting genes including
OCT4, SOX2, NANOG, and LIN28 was confirmed by quantitative real-
time PCR (Fig. 1C), and by immunocytochemistry staining for Nanog,
Oct-4, TRA-1-81, and SSEA4 (Fig. 1A). The clearance of the Sendai virus
was confirmed at passage 11 (Fig. 1D). The alkaline phosphatase
Fig. 1. Characterization of MADGIC 4A iPSC line.
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staining was positive (Fig. 1B), and chromosomal analysis showed a
normal karyotype (Fig. 1E). STR analysis confirmed identical genetic
background of the donor fibroblasts and the iPSC clone (data available
from the authors). To confirm the presence of the missense mutation, a
DNA sample from the iPSC clone was sequenced for the APP loci, which
confirmed a heterozygous c.2017G>A transition (Fig. 1F). In addition,
MADGIC 4A line formed embryoid bodies (EBs) when plated in low
adherent plate. Immunocytochemical analyses of the EBs were per-
formed after 14 days of culture and showed a spontaneous differentia-
tion into cell types representative of the three embryonic germ layers,
including smooth muscle antibody (SMA)-positive cells (mesoderm),
alpha-fetoprotein (AFP)-positive cells (endoderm) and beta-III-tubulin
(B-III-TUB)-positive cells (ectoderm) (Fig. 1G). A luminescence-based




Skin biopsy-derived fibroblasts were obtained from a patient re-
cruited by Kuopio University Hospital in Finland, after obtaining in-
formed consent. The fibroblasts were expanded in fibroblast culture
media containing Iscove's DMEM media (Thermo Fisher Scientific) with




Classification Test Result Data
Morphology Photography Visual record of the line: normal Not shown but available with
author
Phenotype Immunocytochemistry Positive staining of pluripotency markers: Oct4, Nanog, TRA-1-
81, SSEA4
Fig. 1 panel A
Alkaline Phosphatase activity Fig. 1 panel B
Visible activity
RT-qPCR Expression of Nanog Fig. 1 panel C
Lin28, Oct4, Sox2
Genotype Karyotype (G-banding) and resolution 46 XY Fig. 1 panel E
Resolution of 400 band level
Identity STR analysis 7 sites tested, all matched with parental fibroblasts cell line Available with author
Mutation analysis Sequencing Heterozygous Fig. 1 panel F
p.A673T in APP
Microbiology and virology Mycoplasma Mycoplasma testing by luminescence. Negative. Not shown but available with
the author
Differentiation potential Embryoid body formation Positive staining for α-feto protein (AFP), smooth muscle actin
(SMA) and beta-III-tubulin (BIIITub)
Fig. 1 panel G
Donor screening (OPTIONAL) HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-Oct4 1:400 EMD Millipore; cat.MAB4401
Goat anti-Nanog 1:100 R&D Systems; cat. AF1997
Mouse anti-SSEA4 1:400 EMD Millipore; cat. MAB4304
Mouse anti-TRA-1-81 1:200 EMD Millipore; cat. MAB4381
Differentiation markers Mouse anti-SMA 1:300 Sigma-Aldrich; cat. A5228
Mouse anti-AFP 1:300 Sigma-Aldrich; cat. A8452
Mouse anti-B -III-tubulin 1:1000 Covance; cat. MMS-435P
Secondary antibodies Goat anti-mouse Alexa Fluor 488 1:300 Molecular Probes, cat. A11001
Goat anti-mouse Alexa Fluor 568 1:300 Molecular Probes; cat. A11004
Donkey anti-goat Alexa Fluor 568 1:300 Molecular Probes; cat. A11057
Primers
Target Forward/reverse primer (5′-3′)
Mutation analysis/sequencing APP Fw 5′-TGGCAAGACAAACAGTAGTGG-3′
Rev. 5′-CTTGCCAACCTCTCAACCAG-3′
Primers Target Company
Pluripotency markers (qPCR) Nanog Thermo Fisher Scientific; cat. Hs02387400_g1
Lin28 Thermo Fisher Scientific; cat. Hs00702808_s1
Oct4 Thermo Fisher Scientific; cat. Hs00742896_s1
Sox2 Thermo Fisher Scientific; cat. Hs01053049_s1
House-keeping genes (qPCR) ACTB Thermo Fisher Scientific; cat. 4326315E
Sendai virus SeV Thermo Fisher Scientific; cat. Mr04269880_mr
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Generation of induced pluripotent stem cells
For reprogramming, 150,000 cells were plated on a 6-well plate and
maintained in fibroblast culture media for 2 days. The cells at 90%
confluency were transduced using CytoTune™-iPS 2.0 Sendai
Reprogramming Kit (Thermo Fisher Scientific) with three separate
vectors carrying genes hOCT-3/4, hKLF-4, hSOX-2 and hc-MYC to in-
duce pluripotency. The media was changed 24 h after transduction and
then daily. At day 6, fibroblast culture medium was replaced with
Essential 6 Medium (E6, Thermo Fisher Scientific) supplemented with
100 ng/ml basic fibroblast growth factor (bFGF). On the next day, the
cells are re-plated onto 6-well matrigel-coated plates with a density of
60,000 cells/well. Between days 17–28, the individual colonies were
picked to 24-well matrigel-coated plate containing Essential 8 Medium
(E8, Thermo Fisher Scientific) and passaged with 0.5 mM EDTA weekly.
One week later, four colonies were selected and expanded on 6-well
plates with daily media changes (Table 1).
Characterization of pluripotency by RT-qPCR and immunocytochemistry
The total RNA from the iPSCs was extracted using RNeasy Mini kit
(Qiagen), and synthesis of cDNA was carried out using Maxima reverse
transcriptase enzyme approach (Thermo Fisher Scientific). Maxima
Probe qPCR Master Mix (Thermo Fisher Scientific) and commercially
available Taqman probes (Table 2) were used in qPCR measurement by
StepOne Plus machine. For immunocytochemistry, plated iPSCs were
fixed in 4% paraformaldehyde for 20min at room temperature (RT),
permeabilized with 0.2% Triton X-100 (in case of Nanog and Oct-4),
blocked in 5% normal goat serum at RT for 1 h and finally incubated
with the primary antibodies (Table 2) overnight at 4 °C. On the fol-
lowing day, the secondary antibodies (1:300 dilution) were added for
1 h at RT. Images were taken using a Zeiss AXIO microscope. Scale bars
are 100 μm.
Alkaline phosphatase activity
Plated iPSCs were stained with Nitro blue tetrazolium chloride/5-
Bromo-4-chloro-3-indolyl phosphate, toluidine salt) (Roche) at a dilu-
tion of 1:50 in buffer containing 100mM Tris-HCl pH 8.2–8.5, 100mM
NaCl, 50mM MgCl2 and incubated for 20min in the dark before ima-
ging.
Embryoid body formation
Pluripotency was confirmed by EB-based differentiation. Small un-
differentiated iPSCs colonies were lifted up by scalpel to ultra low-ad-
herent dishes (Corning) and cultured in DMEM media (Thermo Fisher
Scientific) supplemented with 20% serum replacement and 1%
Penicillin-Streptomycin. Afterwards, EBs were plated onto Matrigel-
coated 24-well plates and left to differentiate for two weeks. Scale bar
for EBs is 100 μm. Scale bars for differentiated cells are 50 μm.
Karyotype analysis
Karyotyping was performed using Giemsa (G-banding) staining,
after arresting the cells in the metaphase by 200 ng/mlN-desacetyl-N-
methyl colchicine. The analyses were performed at the Yhtyneet Medix
laboratoriot, Finland (http://www.yml.fi/).
Genetic analysis
Genomic DNA was isolated from the parental fibroblasts and the
iPSC clones with geneJET genomic DNA purification kit (Thermo Fisher
Scientific). To verify the genetic identity of the clones seven micro-
satellite loci were analyzed by PCR and gel electrophoresis (primer
sequences available upon request). Further, the presence of the muta-
tion was confirmed by PCR and Sanger sequencing (Primers listed in
Table 2, Fw-primer used for sequencing.)
Mycoplasma testing
The absence of mycoplasma contamination was confirmed using the
MycoAlert™ Mycoplasma Detection Kit (Lonza).
Acknowledgment
We thank Laila Kaskela and Eila Korhonen for their outstanding
technical assistance.
This work is part of an EU Joint Programme - Neurodegenerative
Disease Research (JPND) project and supported by Suomen Akatemia
under grant No 301253 and the European Union's Horizon 2020 re-
search and innovation programme under grant agreement No 643417.
References
Holmqvist, S., Lehtonen, Š., Chumarina, M., Puttonen, K.A., Azevedo, C., Lebedeva, O.,
Ruponen, M., Oksanen, M., Djelloul, M., Collin, A., et al., 2016. Creation of a library
of induced pluripotent stem cells from Parkinsonian patients. NPJ Park. Dis. 2,
16009.
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J., Jonsson, P.V., Bjornsson, S.,
Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al., 2012. A mutation in
APP protects against Alzheimer's disease and age-related cognitive decline. Nature
488, 96–99.
Martiskainen, H., Herukka, S.-K., Stančáková, A., Paananen, J., Soininen, H., Kuusisto, J.,
Laakso, M., Hiltunen, M., 2017. Decreased plasma β-amyloid in the Alzheimer's
disease APPA673T variant carriers. Ann. Neurol. 82 (1), 128–132.
Š. Lehtonen et al. Stem Cell Research 30 (2018) 96–99
99
